ClinicalTrialsFinder
RecruitingPhase 3NCT07617597

Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adult Patients With Severe Alopecia Areata With an Open-Label Extension Period

Sponsor

Sun Pharma Japan Limited

Enrollment

78 participants

Start Date

Jun 19, 2026

Study Type

INTERVENTIONAL

Conditions

Alopecia Areata

Summary

This study evaluates the efficacy and safety of deuruxolitinib in Japanese Adults between 18 and 65 years of age who have 50% or greater scalp hair loss.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Deuruxolitinib and a drug called Placebo for people with alopecia areata. The study is currently recruiting participants at 18 locations. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDeuruxolitinib

Deuruxolitinib will be dosed orally as tablets at a dose of 8 mg

DRUGPlacebo

Deuruxolitinib matching placebo will be dosed orally as tablets for up to 24 weeks and then deuruxolitinib will be dosed for up to 52 weeks

Locations(18)

Study Site 102

Asahikawa, Japan

Study Site 117

Bunkyō City, Japan

Study Site 119

Ebina, Japan

Study Site 101

Hamamatsu, Japan

Study Site 116

Ishikawa, Japan

Study Site 112

Kitakyushu, Japan

Study Site 118

Kōtoku, Japan

Study Site 110

Kurashiki, Japan

Study Site 113

Kurume, Japan

Study Site 107

Kyoto, Japan

Study Site 106

Mitaka-shi, Japan

Study Site 114

Miyagi-gun, Japan

Study Site 104

Niigata, Japan

Study Site 109

Osaka, Japan

Study Site 108

Osaka, Japan

Study Site 103

Sapporo, Japan

Study Site 105

Shinjuku-Ku, Japan

Study Site 111

Ube, Japan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07617597

Related Trials

A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)

NCT0753300630 locations

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

NCT06012240281 locations

Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata

NCT067476111 location

Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata

NCT053988091 location

Regeneron AA Multicenter (Dupilumab)

NCT055517933 locations